Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.

Tytuł:
HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
Autorzy:
Sadiq Q; Department of Pathology, Methodist University Hospital, University of Tennessee Health Sciences Center, Memphis, TN, USA.
Sekhri R; Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, USA.
Dibaba DT; Tennessee Clinical and Translational Science Institute, University of Tennessee Health Science Center, Memphis, TN, USA.; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Zhao Q; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Agarwal S; Department of Pathology, University of New Mexico School of Medicine, MSC08 4640, 1 University of New Mexico, Albuquerque, NM, 87131, USA. .
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2021 May 08; Vol. 19 (1), pp. 143. Date of Electronic Publication: 2021 May 08.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, 2003-
MeSH Terms:
Adenocarcinoma, Follicular*/diagnosis
Thyroid Neoplasms*/diagnosis
Humans ; Prognosis ; Thyroid Cancer, Papillary
References:
Hum Pathol. 2018 Apr;74:1-4. (PMID: 29339178)
Endocr Pathol. 2006 Fall;17(3):213-23. (PMID: 17308358)
Pathol Res Pract. 2020 Mar;216(3):152678. (PMID: 31740230)
Endocr Pathol. 2018 Sep;29(3):242-249. (PMID: 29508145)
Cytojournal. 2009 Sep 18;6:18. (PMID: 19826479)
JAMA. 2017 Apr 4;317(13):1338-1348. (PMID: 28362912)
Endocr Pathol. 2018 Jun;29(2):91-112. (PMID: 29744727)
Am J Clin Pathol. 2008 Nov;130(5):736-44. (PMID: 18854266)
Am J Clin Pathol. 2006 Nov;126(5):700-8. (PMID: 17050067)
Mod Pathol. 2016 Jul;29(7):698-707. (PMID: 27102347)
Arch Pathol Lab Med. 2003 May;127(5):579-83. (PMID: 12708901)
Mod Pathol. 2005 Jan;18(1):48-57. (PMID: 15272279)
Am J Surg Pathol. 2003 Aug;27(8):1177-9. (PMID: 12883256)
Cell. 2014 Oct 23;159(3):676-90. (PMID: 25417114)
Endocr Pathol. 2019 Jun;30(2):155-162. (PMID: 30953289)
Endocr Pathol. 2005 Winter;16(4):295-309. (PMID: 16627917)
Thyroid. 2017 Jun;27(6):802-810. (PMID: 28293988)
Cancer. 2000 Oct 25;90(5):307-11. (PMID: 11038428)
Diagn Cytopathol. 2008 Jun;36(6):438-41. (PMID: 18478603)
Mod Pathol. 1997 Jul;10(7):668-74. (PMID: 9237176)
Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6. (PMID: 716909)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
Endocr Relat Cancer. 2016 Dec;23(12):893-897. (PMID: 27660403)
World J Surg. 2018 Feb;42(2):321-326. (PMID: 28828746)
Pathol Int. 2018 Jun;68(6):327-333. (PMID: 29675873)
JAMA Oncol. 2016 Aug 1;2(8):1023-9. (PMID: 27078145)
Thyroid. 2013 Oct;23(10):1256-62. (PMID: 23477374)
Diagn Pathol. 2010 Jan 26;5:9. (PMID: 20181018)
Mod Pathol. 2018 Jan;31(1):39-55. (PMID: 29052599)
Thyroid. 2017 Apr;27(4):512-517. (PMID: 28136139)
Clinics (Sao Paulo). 2018 May 21;73:e576. (PMID: 29791602)
Endocr Pathol. 2003 Spring;14(1):55-60. (PMID: 12746563)
J Clin Endocrinol Metab. 2017 Jan 1;102(1):15-22. (PMID: 27732333)
Adv Anat Pathol. 2018 May;25(3):172-179. (PMID: 29351089)
Endocr Pathol. 2016 Sep;27(3):224-32. (PMID: 27153840)
Endocr Pathol. 2018 Sep;29(3):231-235. (PMID: 29978374)
Am J Surg Pathol. 2002 Nov;26(11):1508-14. (PMID: 12409728)
Am J Clin Pathol. 2001 Nov;116(5):696-702. (PMID: 11710686)
Mod Pathol. 2017 Jun;30(6):810-825. (PMID: 28281551)
Arch Pathol Lab Med. 2015 Jan;139(1):67-82. (PMID: 25549145)
Am J Surg Pathol. 1977 Jun;1(2):123-30. (PMID: 602974)
Hum Pathol. 1999 Oct;30(10):1166-71. (PMID: 10534163)
Endocr Pathol. 2005 Spring;16(1):63-6. (PMID: 16000848)
Am J Surg Pathol. 2004 Oct;28(10):1336-40. (PMID: 15371949)
Malays J Pathol. 2017 Apr;39(1):55-67. (PMID: 28413206)
Endocrine. 2019 Apr;64(1):97-108. (PMID: 30689169)
Mod Pathol. 2006 Dec;19(12):1631-7. (PMID: 16998461)
Endocr Relat Cancer. 2005 Jun;12(2):305-17. (PMID: 15947105)
J Clin Endocrinol Metab. 2014 Feb;99(2):E276-85. (PMID: 24248188)
Int J Clin Exp Med. 2015 Mar 15;8(3):4369-74. (PMID: 26064355)
Contributed Indexing:
Keywords: CK19; Follicular; HBME1; NIFTP; Papillary
Entry Date(s):
Date Created: 20210509 Date Completed: 20210514 Latest Revision: 20210514
Update Code:
20240105
PubMed Central ID:
PMC8106857
DOI:
10.1186/s12957-021-02258-7
PMID:
33964951
Czasopismo naukowe
Background: Thyroid neoplasms with follicular architecture can have overlapping morphologic features and pose diagnostic confusion among pathologists. Various immunohistochemical stains have been investigated as potential diagnostic markers for PTC, among which HBME1 and CK19 have gained popularity. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) poses similar diagnostic challenges with interobserver variability and is often misdiagnosed as adenomatoid nodule or follicular adenoma. This study aims to evaluate expression of HBME1 and CK19 in NIFTPs in comparison to other well-differentiated thyroid neoplasms and benign mimickers.
Method: Seventy-three thyroid cases diagnosed over a period of 3 years at Methodist University Hospital, Memphis, TN, USA, were included in this study: 9 NIFTP; 18 papillary thyroid carcinoma (PTC); 11 follicular variant of papillary thyroid carcinoma, invasive (I-FVPTC); 24 follicular adenomas (FA); and 11 multinodular goiters/adenomatoid nodules (MNG). A tissue microarray (TMA) was constructed and HBME1 and CK19 immunohistochemistry was performed.
Results: 77.8% of NIFTPs, 88.9% of PTCs, 81.8% of I-FVPTCs, 16.7% of FAs, and 18.2% of MNGs showed HBME-1 expression. 66.7% of NIFTPs, 83.3% of PTCs, 81.8% of I-FVPTCs, 33.3% of FAs, and 45.4% of MNGs expressed CK19. Difference in expression of HBME1 and CK19 was statistically significant for NIFTP vs FA (qualitative; p < 0.05) and NIFTP vs MNG (p < 0.05). No statistically significant difference was found for HBME1 in NIFTP vs PTC (conventional and FVPTC), p ≥ 0.2. Sensitivity of HBME1 and CK19 for NIFTP were 78% and 67%, ~ 88% each for PTC, and 89% and 100% for FVPTC, respectively, while specificity of HBME1 and CK19 for NIFTP were 53% each, ~ 62% each for PTC, and ~55% each for FVPTC.
Conclusion: Our study indicated that HBME1 and CK19 are valuable markers in differentiating NIFTPs from morphologic mimics like follicular adenoma and adenomatoid nodules/multinodular goiter. While HBME1 and CK19 are both sensitive in diagnosing lesions with PTC-like nuclear features, CK19 stains a higher number of benign lesions in comparison to HBME1. No increase in sensitivity or specificity in diagnosis of NIFTP, PTC, or FVPTC was noted on combining the two antibodies.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies